TARA

Protara Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website rotaratx.com
Employees(FY) 25
ISIN US74365U1079

Performance

-10.47%

+20.94%

+8.45%

-25.24%

+23.19%

YTD

+100.87%

Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of TARA 2024-11-20

The stock indicators reflect a neutral sentiment, with the Moving Average Score, Oscillators Score, and Technical Score all at 50, indicating a balanced market condition without strong bullish or bearish signals. This suggests that investors may be in a wait-and-see mode, as there is no clear direction in the current price action.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TARA

Stock Rank

Recent News & Updates

2024-11-15 04:52
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology(Globenewswire)
2024-11-11 19:00
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-11-05 19:00
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference(Globenewswire)
2024-10-20 20:00
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support(Globenewswire)
2024-09-08 20:05
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations(Globenewswire)
2024-09-08 20:00
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support(Globenewswire)
2024-09-02 20:00
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-05 20:00
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-06-24 05:06
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-05-20 20:00
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit(Globenewswire)
2024-05-02 00:54
TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-01 20:00
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-04-11 21:55
Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now(Zacks)
2024-04-04 20:04
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing(Globenewswire)
2024-04-04 20:02
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition(Globenewswire)
2024-04-04 20:00
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC(Globenewswire)
2024-03-12 20:00
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update(Globenewswire)
2024-02-27 19:00
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference(Globenewswire)
2024-01-30 18:30
Protara Therapeutics to Participate in Upcoming Investor Conferences(Globenewswire)
2023-11-29 19:30
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology(Globenewswire)
2023-11-02 21:43
Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results(Yahoo Finance)
2023-11-02 20:00
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update(Globenewswire)
2023-10-22 20:00
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations(Globenewswire)
2023-09-19 20:30
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ(Yahoo Finance)
2023-09-04 19:30
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-02 20:00
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update(Yahoo Finance)
2023-05-14 20:00
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ(Yahoo Finance)
2023-05-03 20:00
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update(Yahoo Finance)
2023-05-01 20:00
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations(Yahoo Finance)
2023-04-27 20:00
Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.